Secukinumab Medicine 04 June 2026 Extended indication Extension of indication to include treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents 12 years and older with an inadequate response to conventional systemic HS therapy for COSENTYX Therapeutic value Total cost Registration phase Registration application pending Product Active substance Secukinumab Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Other chronic immune diseases Extended indication Extension of indication to include treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents 12 years and older with an inadequate response to conventional systemic HS therapy for COSENTYX Current proprietary name Already available biosimilars / generics Proprietary name Cosentyx Manufacturer Novartis Portfolio holder Novartis Mechanism of action Interleukin inhibitor Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Particularity ATMP Submission date April 2026 Expected Registration March 2027 Orphan drug Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks